Publications by authors named "Hans R Brunner"

Claim this Profile
A
Angiotensin II type 1 receptor antagonists in animal models of vascular, cardiac, metabolic and renal disease.
Martin C Michel, Hans R Brunner, Carolyn Foster, Yong Huo

Pharmacol Ther· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Aldosterone synthase inhibition for the treatment of hypertension and the derived mechanistic requirements for a new therapeutic strategy.
Christoph D Schumacher, Ronald E Steele, Hans R Brunner

J Hypertens· October 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A systematic comparison of the properties of clinically used angiotensin II type 1 receptor antagonists.
Martin C Michel, Carolyn Foster, Hans R Brunner, Lisheng Liu

Pharmacol Rev· April 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cardiovascular outcomes in hypertensive patients: comparing single-agent therapy with combination therapy.
Michael A Weber, Stevo Julius, Sverre E Kjeldsen, Yan Jia, Hans R Brunner

J Hypertens· November 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antihypertensive efficacy of olmesartan medoxomil and candesartan cilexetil assessed by 24-hour ambulatory blood pressure monitoring in patients with essential hypertension.
Hans R Brunner, Klaus O Stumpe, Andrzej Januszewicz

Clin Drug Investig· October 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Usefulness of heart rate to predict cardiac events in treated patients with high-risk systemic hypertension.
Stevo Julius, Paolo Palatini, Sverre E Kjeldsen, Alberto Zanchetti, Michael A Weber, Hans R Brunner

Am J Cardiol· March 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Practical solutions to the challenges of uncontrolled hypertension: a white paper.
Josep Redon, Hans R Brunner, Claudio Ferri, Karl F Hilgers, Rainer Kolloch

J Hypertens Suppl· December 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Under pressure: future prospects in hypertension management. Interview by Laura Dormer.
Hans R Brunner

Expert Rev Cardiovasc Ther· August 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Aliskiren: the first renin inhibitor for clinical treatment.
Chris Jensen, Peter Herold, Hans Rudolf Brunner

Nat Rev Drug Discov· May 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evolution and hypertension: is the Renin system necessary?
Haralambos Gavras, Hans R Brunner

Hypertension· June 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Olmesartan medoxomil: current status of its use in monotherapy.
Hans R Brunner

Vasc Health Risk Manag· March 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antihypertensive efficacy of olmesartan medoxomil and candesartan cilexetil in achieving 24-hour blood pressure reductions and ambulatory blood pressure goals.
Hans R Brunner, Kikuo Arakawa

Clin Drug Investig· February 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Validation of in-vitro data by in-vivo evidence: the example of angiotensin (1-7).
Hans R Brunner, Haralambos Gavras

J Hypertens· October 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) trial: outcomes in patients receiving monotherapy.
Stevo Julius, Michael A Weber, Sverre E Kjeldsen, Gordon T McInnes, Alberto Zanchetti, Hans R Brunner

Hypertension· September 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sustained 24-hour blockade of the renin-angiotensin system: a high dose of a long-acting blocker is as effective as a lower dose combined with an angiotensin-converting enzyme inhibitor.
Christopher Hasler, Jürg Nussberger, Marc Maillard, Andrei Forclaz, Hans R Brunner

Clin Pharmacol Ther· November 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neuropeptide Y expression, localization and cellular transducing effects in HUVEC.
Antonio P Silva, Jocelyne E Kaufmann, Cécile Vivancos, Stanislav Fakan, Claudia Cavadas, Hans R Brunner

Biol Cell· June 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Endogenous angiotensin II induces atherosclerotic plaque vulnerability and elicits a Th1 response in ApoE-/- mice.
Lucia Mazzolai, Michel A Duchosal, Martine Korber, Karima Bouzourene, Jean François Aubert, Hans-R Brunner

Hypertension· September 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Renal endothelin receptor type B upregulation in rats with low or high renin hypertension.
Noureddine Brakch, Saad Abdel-Sayed, Flore Allemandou, Qing Wang, Jean F Aubert, Hans R Brunner

J Hypertens· September 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical efficacy and tolerability of olmesartan.
Hans R Brunner

Clin Ther· August 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial.
Stevo Julius, Sverre E Kjeldsen, Michael Weber, Hans R Brunner, Steffan Ekman

Lancet· June 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial.
Michael A Weber, Stevo Julius, Sverre E Kjeldsen, Hans R Brunner, Steffan Ekman

Lancet· June 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Determination of cardiac contractility in awake unsedated mice with a fluid-filled catheter.
Qing Wang, Hans R Brunner, Michel Burnier

Am J Physiol Heart Circ Physiol· February 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Angiotensin II receptor blockade prevents acute renal sodium retention induced by low levels of orthostatic stress.
Grégoire Wuerzner, Arnaud Chioléro, Marc Maillard, Jürg Nussberger, Hans R Brunner

Kidney Int· January 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Volume expansion enhances plasma endothelin-1.
Saad Abdel-Sayed, Hans Rudolf Brunner, Juerg Nussberger

Am J Hypertens· December 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
NPY, NPY receptors, and DPP IV activity are modulated by LPS, TNF-alpha and IFN-gamma in HUVEC.
Antonio P Silva, Claudia Cavadas, Bénédicte Baïsse-Agushi, Olivier Spertini, Hans R Brunner

Regul Pept· November 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis